Department of General Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, 210008, China; Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, 210008, China.
Department of Clinic Nutrition, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, 210008, China.
Biochem Biophys Res Commun. 2024 Jul 30;719:150084. doi: 10.1016/j.bbrc.2024.150084. Epub 2024 May 8.
Colorectal cancer (CRC) is a prevalent digestive malignancy with significant global mortality and morbidity rates. Improving diagnostic capabilities for CRC and investigating novel therapeutic approaches are pressing clinical imperatives. Additionally, carcinoembryonic antigen (CEA) has emerged as a highly promising candidate for both colorectal tumor imaging and treatment.
A novel active CEA-targeting nanoparticle, CEA(Ab)-MSNs-ICG-Pt, was designed and synthesized, which served as a tumor-specific fluorescence agent to help in CRC near-infrared (NIR) fluorescence imaging. In cell studies, CEA(Ab)-MSNs-ICG-Pt exhibited specific targeting to RKO cells through specific antibody-antigen binding of CEA, resulting in distribution both within and around these cells. The tumor-targeting-specific imaging capabilities of the nanoparticle were determined through in vivo fluorescence imaging experiments. Furthermore, the efficacy of the nanoparticle in delivering chemotherapeutics and its killing effect were evaluated both in vitro and in vivo.
The CEA(Ab)-MSNs-ICG-Pt nanoparticle, designed as a novel targeting agent for carcinoembryonic antigen (CEA), exhibited dual functionality as a targeting fluorescent agent. This CEA-targeting nanoparticle showed exceptional efficacy in eradicating CRC cells in comparison to individual treatment modalities. Furthermore, it exhibits exceptional biosafety and biocompatibility properties. CEA(Ab)-MSNs-ICG-Pt exhibits significant promise due to its ability to selectively target tumors through NIR fluorescence imaging and effectively eradicate CRC cells with minimal adverse effects in both laboratory and in vivo environments.
The favorable characteristics of CEA(Ab)-MSNs-ICG-Pt offer opportunities for its application in chemotherapeutic interventions, tumor-specific NIR fluorescence imaging, and fluorescence-guided surgical procedures.
结直肠癌（CRC）是一种常见的消化道恶性肿瘤，具有显著的全球死亡率和发病率。提高 CRC 的诊断能力并研究新的治疗方法是迫切的临床需求。此外，癌胚抗原（CEA）已成为结直肠肿瘤成像和治疗的极具前途的候选物。
设计并合成了一种新型的活性 CEA 靶向纳米粒子，CEA(Ab)-MSNs-ICG-Pt，作为肿瘤特异性荧光剂，有助于 CRC 近红外（NIR）荧光成像。在细胞研究中，CEA(Ab)-MSNs-ICG-Pt 通过 CEA 的特异性抗体-抗原结合，对 RKO 细胞表现出特异性靶向，导致其在这些细胞内和周围分布。通过体内荧光成像实验确定了纳米粒子的肿瘤靶向特异性成像能力。此外，还评估了纳米粒子在递送化疗药物方面的功效及其在体外和体内的杀伤效果。
设计为新型癌胚抗原（CEA）靶向剂的 CEA(Ab)-MSNs-ICG-Pt 纳米粒子兼具靶向荧光剂的双重功能。与单独的治疗方式相比，这种 CEA 靶向纳米粒子在根除 CRC 细胞方面表现出卓越的疗效。此外，它还表现出卓越的生物安全性和生物相容性。CEA(Ab)-MSNs-ICG-Pt 具有很大的应用潜力，因为它能够通过近红外荧光成像选择性地靶向肿瘤，并在实验室和体内环境中以最小的不良反应有效地根除 CRC 细胞。
CEA(Ab)-MSNs-ICG-Pt 的有利特性为其在化学治疗干预、肿瘤特异性 NIR 荧光成像和荧光引导手术中的应用提供了机会。
